Early-onset colorectal cancer (CRC) is characterized by distinct molecular and clinical features, a more advanced stage at diagnosis, and unique challenges in clinical management.
Aim
This study aimed to characterize the clinicopathologic features of early-onset CRC and investigate the associations between clinicopathologic characteristics and genetic mutations in young Chinese patients.
Methods
In total, 239 young Chinese patients (age range: 22-45 years) diagnosed with CRC who underwent surgery from January 2016 to June 2022 were retrospectively enrolled. KRAS, NRAS, and BRAF mutations were detected using a mutation analysis panel kit. Mismatch repair (MMR) protein (MLH, PMS2, MSH2, MSH6) expression was evaluated by immunohistochemistry. Pearson's chi-squared test was used to assess the relationships of genetic mutations and MMR with patients’ clinicopathologic characteristics.
Results
The overall KRAS/NRAS/BRAF mutation rate was 50.6% (121/239), including individual rates of 44.4% (KRAS), 2.1% (NRAS), and 4.2% (BRAF). In addition, 15.1% of the patients (36/239) were MMR-deficient (dMMR). The BRAF V600E mutation was significantly associated with high grade (P = .012). Similarly, dMMR status showed significant associations with larger tumor size (P = .028), tumor location (P < .001), the absence of lymph node metastasis (P = .001), and the absence of distant metastasis (P = .038). KRAS mutations were more frequent in dMMR tumors than in MMR-proficient tumors (63.8% vs 40.8%).
Conclusion
Genetic mutations in the RAS/RAF pathway and dMMR status are associated with distinct clinicopathological features in patients with early-onset CRC. dMMR is a potentially favorable prognostic marker.
HanB, ZhengR, ZengH, et al.Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47-53. doi:10.1016/j.jncc.2024.01.006
2.
SungH, SiegelRL, LaversanneM, et al.Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data. Lancet Oncol. 2025;26(1):51-63. doi:10.1016/S1470-2045(24)00600-4
3.
PanH, ZhaoZ, DengY, et al.The global, regional, and national early-onset colorectal cancer burden and trends from 1990 to 2019: results from the Global Burden of Disease Study 2019. BMC Public Health. 2022;22(1):1896. doi:10.1186/s12889-022-14274-7
AndreT, ShiuKK, KimTW, et al.Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207-2218. doi:10.1056/NEJMoa2017699
6.
MaioM, AsciertoPA, ManzyukL, et al.Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929-938. doi:10.1016/j.annonc.2022.05.519
7.
YeJX, LiuY, QinY, ZhongHH, YiWN, ShiXY. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol. 2015;21(5):1595-1605. doi:10.3748/wjg.v21.i5.1595
8.
LiQH, WangYZ, TuJ, et al.Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterol Rep (Oxf). 2020;8(3):179-191. doi:10.1093/gastro/goaa026
9.
De RoockW, De VriendtV, NormannoN, CiardielloF, TejparS. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594-603. doi:10.1016/S1470-2045(10)70209-6
10.
VaughnCP, ZobellSD, FurtadoLV, BakerCL, SamowitzWS. Frequency of KRAS. BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011;50(5):307-312. doi:10.1002/gcc.20854
11.
TranB, KopetzS, TieJ, et al.Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20):4623-4632. doi:10.1002/cncr.26086
12.
BardhanK, LiuK. Epigenetics and colorectal cancer pathogenesis. Cancers (Basel).2013;5(2):676-713. doi:10.3390/cancers5020676
13.
KocarnikJM, ShiovitzS, PhippsAI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf). 2015;3(4):269-276. doi:10.1093/gastro/gov046
14.
KudryavtsevaAV, LipatovaAV, ZaretskyAR, et al.Important molecular genetic markers of colorectal cancer. Oncotarget. 2016;7(33):53959-53983. doi:10.18632/oncotarget.9796
15.
HossainMS, KaruniawatiH, JairounAA, et al.Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers (Basel).2022;14(7):1732. doi:10.3390/cancers14071732
16.
ZhangJ, ZhengJ, YangY, et al.Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. Sci Rep. 2015;5:18678. doi:10.1038/srep18678.
17.
KoulouridiA, KaragianniM, MessaritakisI, et al.Prognostic value of KRAS mutations in colorectal cancer patients. Cancers (Basel).2022;14(14):3320. doi:10.3390/cancers14143320
18.
ParkSB, YoonJY, KwakMS, ChaJM. Clinical and pathological characteristics of early-onset colorectal cancer in South Korea. Saudi J Gastroenterol. 2023;29(6):358-364. doi:10.4103/sjg.sjg_35_23
19.
KundrandaMN, KemkesAC, EvansMC, et al.Associations with other cancer-related biomarkers might contribute to poor outcomes in RAS-altered, younger patients with colorectal cancer. Oncologist. 2024;29(9):e1228-e1230. doi:10.1093/oncolo/oyae153
20.
BallesterV, RashtakS, BoardmanL. Clinical and molecular features of young-onset colorectal cancer. World J Gastroenterol. 2016;22(5):1736-1744. doi:10.3748/wjg.v22.i5.1736
21.
EnweremN, ChoMY, DembJ, et al.Systematic review of prevalence, risk factors, and risk for metachronous advanced neoplasia in patients with young-onset colorectal adenoma. Clin Gastroenterol Hepatol. 2021;19(4):680-689 e12. doi:10.1016/j.cgh.2020.04.092
22.
BushyheadD, LinOST, KozarekRA. A review of the management of sporadic colorectal adenomas in young people: is surveillance wasted on the young?Dig Dis Sci.2019;64(8):2107-2112. doi:10.1007/s10620-019-05521-w
23.
NagtegaalID, OdzeRD, KlimstraD, et al.The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188. doi:10.1111/his.13975
24.
CremoliniC, RossiniD, Dell'AquilaE, et al.Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5(3):343-350. doi:10.1001/jamaoncol.2018.5080
ChoMY, SiegelDA, DembJ, RichardsonLC, GuptaS. Increasing colorectal cancer incidence before and after age 50: implications for screening initiation and promotion of “On-Time” screening. Dig Dis Sci.2022;67(8):4086-4091. doi:10.1007/s10620-021-07213-w
27.
MediciB, RiccoB, CaffariE, et al.Early onset metastatic colorectal cancer: current insights and clinical management of a rising condition. Cancers (Basel).2023;15(13):3509. doi:10.3390/cancers15133509
28.
YeZL, QiuMZ, TangT, et al.Gene mutation profiling in Chinese colorectal cancer patients and its association with clinicopathological characteristics and prognosis. Cancer Med. 2020;9(2):745-756. doi:10.1002/cam4.2727
29.
YangQ, HuoS, SuiY, et al.Mutation status and immunohistochemical correlation of KRAS, NRAS, and BRAF in 260 Chinese colorectal and gastric cancers. Front Oncol. 2018;8:487. doi:10.3389/fonc.2018.00487
30.
GuoTA, WuYC, TanC, et al.Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: a single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer. Int J Cancer. 2019;145(6):1625-1634. doi:10.1002/ijc.32489
31.
Mirzapoor AbbasabadiZ, Hamedi AslD, RahmaniB, et al.KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients. J Clin Lab Anal. 2023;37(5):e24868. doi:10.1002/jcla.24868
32.
WuJB, LiXJ, LiuH, LiuYJ, LiuXP. Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer. Biomed Rep. 2023;19(6):104. doi:10.3892/br.2023.1686
33.
WangW, WangR, HanX, ZhangW, ZhuL, GuY. Epidemiological and clinicopathological features of KRAS, NRAS, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer. Medicine (Baltimore). 2024;103(14):e37693. doi:10.1097/MD.0000000000037693
34.
ZhengG, TsengLH, HaleyL, et al.Clinical validation of coexisting driver mutations in colorectal cancers. Hum Pathol. 2019;86:12-20. doi:10.1016/j.humpath.2018.11.014
35.
De RoockW, ClaesB, BernasconiD, et al.Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753-762. doi:10.1016/S1470-2045(10)70130-3
36.
RussoAL, BorgerDR, SzymonifkaJ, et al.Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 2014;120(10):1482-1490. doi:10.1002/cncr.28599
37.
YokotaT, UraT, ShibataN, et al.BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104(5):856-862. doi:10.1038/bjc.2011.19
38.
MillingtonGW. Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949-54). Clin Exp Dermatol. 2013;38(2):222-223. doi:10.1111/ced.12015
39.
ChenD, HuangJF, LiuK, et al.BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2014;9(3):e90607. doi:10.1371/journal.pone.0090607
40.
SienaS, Sartore-BianchiA, Di NicolantonioF, BalfourJ, BardelliA. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101(19):1308-1324. doi:10.1093/jnci/djp280
41.
LeDT, DurhamJN, SmithKN, et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413. doi:10.1126/science.aan6733
FearonER, VogelsteinB. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767. doi:10.1016/0092-8674(90)90186-i
44.
ZwartK, van der BaanFH, CohenR, et al.Prognostic value of lynch syndrome, BRAF(V600E), and RAS mutational status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts. Cancer Med. 2023;12(15):15841-15853. doi:10.1002/cam4.6223
